Carlos Fernández de Larrea Selected Research

Carlos Fernández de Larrea Research Topics

Disease

20	Multiple Myeloma 04/2022 - 01/2011
8	Immunoglobulin Light-chain Amyloidosis 12/2021 - 02/2008
5	Neoplasms (Cancer) 04/2022 - 11/2018
5	Monoclonal Gammopathy of Undetermined Significance 10/2021 - 01/2015
5	Disease Progression 01/2021 - 07/2011
4	Tuberculosis (Tuberculoses) 01/2021 - 03/2002
3	Paraproteinemias (Monoclonal Gammopathy) 04/2021 - 02/2009
3	Hemorrhage 10/2020 - 02/2008
3	Smoldering Multiple Myeloma 01/2018 - 03/2016
3	Amyloidosis 12/2017 - 01/2017
3	Pathologic Complete Response 01/2014 - 01/2011
2	Lymphoma (Lymphomas) 04/2022 - 01/2021
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2021 - 01/2020
2	Waldenstrom Macroglobulinemia (Macroglobulinemia) 04/2021 - 10/2020
2	Infections 10/2020 - 04/2013
1	Leukemia 04/2022
1	Hematologic Neoplasms (Hematological Malignancy) 12/2021
1	Cytokine Release Syndrome 07/2021
1	Thrombotic Microangiopathies 01/2021
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2021
1	Atrial Fibrillation 10/2020
1	Contusions 10/2020
1	Diarrhea 10/2020
1	Edema (Dropsy) 10/2020
1	Neutropenia 10/2020
1	Pneumonia (Pneumonitis) 10/2020
1	Spasm (Spasms) 10/2020
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2020
1	Fever (Fevers) 01/2020
1	Plasmacytoma 05/2019
1	Bites and Stings (Sting) 11/2018
1	Pain (Aches) 10/2018
1	Amyloid Plaque 04/2015
1	Transthyretin-Related Hereditary Amyloidosis 04/2015
1	Pulmonary Tuberculosis 04/2013
1	Residual Neoplasm 07/2012
1	Pleural Effusion (Pleural Effusions) 03/2011

Drug/Important Bio-Agent (IBA)

5	Biomarkers (Surrogate Marker)IBA 04/2022 - 07/2012
5	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 02/2009
4	Chimeric Antigen ReceptorsIBA 12/2021 - 11/2018
4	B-Cell Maturation AntigenIBA 12/2021 - 01/2020
4	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 12/2021 - 01/2020
4	Bortezomib (Velcade)FDA Link 11/2021 - 02/2009
4	Proteins (Proteins, Gene)FDA Link 10/2021 - 01/2018
3	Amyloid (Amyloid Fibrils)IBA 12/2021 - 04/2015
3	Lenalidomide (CC 5013)FDA Link 01/2021 - 09/2015
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2020 - 02/2008
3	AntigensIBA 11/2018 - 09/2008
3	Immunoglobulins (Immunoglobulin)IBA 03/2016 - 01/2011
2	Monoclonal AntibodiesIBA 04/2022 - 11/2018
2	Immunoglobulin M (IgM)IBA 04/2021 - 12/2017
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 09/2015
2	Complement System Proteins (Complement)IBA 01/2021 - 12/2003
2	Peptides (Polypeptides)IBA 01/2021 - 04/2013
2	Immunoglobulin G (IgG)IBA 10/2018 - 02/2009
2	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 06/2018 - 09/2015
2	Oligoclonal BandsIBA 08/2017 - 01/2011
2	Tuberculin (PPD)IBA 12/2003 - 03/2002
1	Melphalan (Alkeran)FDA LinkGeneric 11/2021
1	Interleukin-2 (IL2)IBA 07/2021
1	CytokinesIBA 07/2021
1	Interleukin-15 (Interleukin 15)IBA 07/2021
1	Proteasome InhibitorsIBA 01/2021
1	Etoposide (VP 16)FDA LinkGeneric 01/2021
1	Thalidomide (Thalomid)FDA Link 01/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021
1	Cisplatin (Platino)FDA LinkGeneric 01/2021
1	carfilzomibIBA 01/2021
1	ibrutinibIBA 10/2020
1	Agammaglobulinaemia Tyrosine KinaseIBA 10/2020
1	zanubrutinibIBA 10/2020
1	LigandsIBA 01/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020
1	NectinsIBA 01/2020
1	poliovirus receptorIBA 01/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2020
1	pomalidomideIBA 05/2019
1	ParaproteinsIBA 05/2019
1	Pharmaceutical PreparationsIBA 11/2018
1	AntibodiesIBA 11/2018
1	Immune Checkpoint InhibitorsIBA 11/2018
1	Leukocyte Immunoglobulin-like Receptor B1IBA 01/2018
1	Diphosphonates (Bisphosphonates)IBA 03/2016
1	Immunomodulating AgentsIBA 09/2015
1	Amyloidogenic ProteinsIBA 04/2015
1	MicroRNAs (MicroRNA)IBA 01/2015
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2014
1	ImmunosorbentsIBA 04/2013
1	EnzymesIBA 04/2013
1	Interleukin-12 Subunit p40IBA 03/2011

Therapy/Procedure

9	Therapeutics 12/2021 - 02/2009
9	Stem Cell Transplantation 01/2020 - 02/2008
3	Transplantation 08/2017 - 07/2012
2	Immunotherapy 07/2021 - 11/2018
2	Hematopoietic Stem Cell Mobilization 02/2009 - 02/2008
1	Kidney Transplantation 11/2021
1	Patient Readmission 01/2020
1	Aftercare (After-Treatment) 12/2017
1	Hematopoietic Stem Cell Transplantation 07/2012
1	Induction Chemotherapy 01/2011